Scan to get started on Sahi
Built for active traders and investors
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ | 23K+ Ratings | IFTA Startup of the year 2025 | 7M+ downloads
Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.
Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.
Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks
Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.
Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.
High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news
Alembic Pharmaceuticals Receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension 0.3%/0.1%
Alembic Pharmaceuticals received final USFDA approval for Ciprofloxacin and Dexamethasone Otic Suspension USP (0.3% / 0.1%). The approval strengthens the company's regulatory compliance profile and expands its portfolio of specialized topical formulation offerings for the U.S. generic market.
Punjab & Sind Bank Posts Q2 Standalone Net Profit Of ₹4.1 Billion Versus ₹2.94 Billion YoY
Punjab & Sind Bank recorded a standalone net profit of ₹410 crore for Q2, marking a 39.46% YoY increase from ₹294 crore in the year-ago period. Sequential bottom-line growth also accelerated from the ₹331.51 crore reported in Q1.
Bajaj Healthcare Reports Q2 Standalone Net Profit Of ₹14.1 Crore Vs ₹11.1 Crore YoY
Bajaj Healthcare posted a Q2 standalone net profit of ₹14.1 crore, up 27.03% year-on-year from ₹11.1 crore. The company has scheduled its Q2 earnings call for October 19, 2026 to discuss operational performance.
